Skip to main content
Top
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

Evaluation of early imaging response criteria in glioblastoma multiforme

Authors: Adam Gladwish, Eng-Siew Koh, Jeremy Hoisak, Gina Lockwood, Barbara-Ann Millar, Warren Mason, Eugene Yu, Normand J Laperriere, Cynthia Ménard

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Background

Early and accurate prediction of response to cancer treatment through imaging criteria is particularly important in rapidly progressive malignancies such as Glioblastoma Multiforme (GBM). We sought to assess the predictive value of structural imaging response criteria one month after concurrent chemotherapy and radiotherapy (RT) in patients with GBM.

Methods

Thirty patients were enrolled from 2005 to 2007 (median follow-up 22 months). Tumor volumes were delineated at the boundary of abnormal contrast enhancement on T1-weighted images prior to and 1 month after RT. Clinical Progression [CP] occurred when clinical and/or radiological events led to a change in chemotherapy management. Early Radiologic Progression [ERP] was defined as the qualitative interpretation of radiological progression one month post-RT. Patients with ERP were determined pseudoprogressors if clinically stable for ≥6 months. Receiver-operator characteristics were calculated for RECIST and MacDonald criteria, along with alternative thresholds against 1 year CP-free survival and 2 year overall survival (OS).

Results

13 patients (52%) were found to have ERP, of whom 5 (38.5%) were pseudoprogressors. Patients with ERP had a lower median OS (11.2 mo) than those without (not reached) (p < 0.001). True progressors fared worse than pseudoprogressors (median survival 7.2 mo vs. 19.0 mo, p < 0.001). Volume thresholds performed slightly better compared to area and diameter thresholds in ROC analysis. Responses of > 25% in volume or > 15% in area were most predictive of OS.

Conclusions

We show that while a subjective interpretation of early radiological progression from baseline is generally associated with poor outcome, true progressors cannot be distinguished from pseudoprogressors. In contrast, the magnitude of early imaging volumetric response may be a predictive and quantitative metric of favorable outcome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990,8(7):1277-80.PubMed Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990,8(7):1277-80.PubMed
2.
go back to reference WHO handbook for reporting results of cancer treatment Geneva (Switzerland) 1979. WHO handbook for reporting results of cancer treatment Geneva (Switzerland) 1979.
3.
go back to reference Perry JR, Cairncross JG: Glioma therapies: how to tell which work? J Clin Oncol 2003,21(19):3547-9. 10.1200/JCO.2003.05.885CrossRefPubMed Perry JR, Cairncross JG: Glioma therapies: how to tell which work? J Clin Oncol 2003,21(19):3547-9. 10.1200/JCO.2003.05.885CrossRefPubMed
4.
go back to reference Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Boden K, Eriksson-Alm Y, et al.: Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008,28(2):329-44. 10.1148/rg.282075068CrossRefPubMed Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Boden K, Eriksson-Alm Y, et al.: Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 2008,28(2):329-44. 10.1148/rg.282075068CrossRefPubMed
5.
go back to reference van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM: End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009,27(18):2905-8. 10.1200/JCO.2009.22.4998PubMedCentralCrossRefPubMed van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM: End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009,27(18):2905-8. 10.1200/JCO.2009.22.4998PubMedCentralCrossRefPubMed
6.
go back to reference Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P: Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006,65(2):499-508. 10.1016/j.ijrobp.2005.12.002CrossRefPubMed Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P: Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006,65(2):499-508. 10.1016/j.ijrobp.2005.12.002CrossRefPubMed
7.
go back to reference Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al.: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008,26(13):2192-7. 10.1200/JCO.2007.14.8163CrossRefPubMed Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al.: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008,26(13):2192-7. 10.1200/JCO.2007.14.8163CrossRefPubMed
8.
go back to reference Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al.: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008,113(2):405-10. 10.1002/cncr.23562CrossRefPubMed Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al.: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008,113(2):405-10. 10.1002/cncr.23562CrossRefPubMed
9.
go back to reference Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008,9(5):453-61. 10.1016/S1470-2045(08)70125-6CrossRefPubMed Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008,9(5):453-61. 10.1016/S1470-2045(08)70125-6CrossRefPubMed
10.
go back to reference Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007,67(2):323-6. 10.1016/j.ijrobp.2006.10.010CrossRefPubMed Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007,67(2):323-6. 10.1016/j.ijrobp.2006.10.010CrossRefPubMed
11.
go back to reference Henson JW, Ulmer S, Harris GJ: Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008,29(3):419-24. 10.3174/ajnr.A0963CrossRefPubMed Henson JW, Ulmer S, Harris GJ: Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008,29(3):419-24. 10.3174/ajnr.A0963CrossRefPubMed
12.
go back to reference Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, et al.: Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol 2002,4(4):268-77.PubMedCentralPubMed Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, et al.: Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol 2002,4(4):268-77.PubMedCentralPubMed
13.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000,92(3):205-16. 10.1093/jnci/92.3.205CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000,92(3):205-16. 10.1093/jnci/92.3.205CrossRefPubMed
14.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009,45(2):228-47. 10.1016/j.ejca.2008.10.026CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009,45(2):228-47. 10.1016/j.ejca.2008.10.026CrossRefPubMed
15.
go back to reference Wen PY, Macdonald DR, Reardon DA, van den Bent MJ, Chang SM, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010,28(11):1963-1972. 10.1200/JCO.2009.26.3541CrossRefPubMed Wen PY, Macdonald DR, Reardon DA, van den Bent MJ, Chang SM, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010,28(11):1963-1972. 10.1200/JCO.2009.26.3541CrossRefPubMed
16.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44: 837-845. 10.2307/2531595CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44: 837-845. 10.2307/2531595CrossRefPubMed
17.
go back to reference Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al.: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008,10(2):162-70. 10.1215/15228517-2007-062PubMedCentralCrossRefPubMed Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al.: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008,10(2):162-70. 10.1215/15228517-2007-062PubMedCentralCrossRefPubMed
18.
go back to reference Shankar LK, Van den AA, Yap J, Benjamin R, Scheutze S, FitzGerald TJ: Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res 2009,15(6):1891-7. 10.1158/1078-0432.CCR-08-2030CrossRefPubMed Shankar LK, Van den AA, Yap J, Benjamin R, Scheutze S, FitzGerald TJ: Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res 2009,15(6):1891-7. 10.1158/1078-0432.CCR-08-2030CrossRefPubMed
19.
go back to reference Shah S, Kesari S, Xu R, Batchelor T, O'Neill A, Hochberg F, Levy B, Bradshaw J, Wen P: Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Onc 2006, 8: 38-46. 10.1215/S1522851705000529CrossRef Shah S, Kesari S, Xu R, Batchelor T, O'Neill A, Hochberg F, Levy B, Bradshaw J, Wen P: Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Onc 2006, 8: 38-46. 10.1215/S1522851705000529CrossRef
20.
go back to reference Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV, Erickson BJ: Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuoro Onc 2006,8(2):156-65. 10.1215/15228517-2005-005CrossRef Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV, Erickson BJ: Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuoro Onc 2006,8(2):156-65. 10.1215/15228517-2005-005CrossRef
21.
go back to reference Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK: Response criteria for glioma. Nat Clin Prac Onc 2008,11(5):634-44.CrossRef Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK: Response criteria for glioma. Nat Clin Prac Onc 2008,11(5):634-44.CrossRef
22.
go back to reference Roldán GB, Scot JN, Hamilton MG, Easaw JC, et al.: Population-based study of pseudoprogression after chemotadiotherapy in GBM. Can J Neurol Sci 2009, 36: 617-22.CrossRefPubMed Roldán GB, Scot JN, Hamilton MG, Easaw JC, et al.: Population-based study of pseudoprogression after chemotadiotherapy in GBM. Can J Neurol Sci 2009, 36: 617-22.CrossRefPubMed
23.
go back to reference Sanghera P, Perry J, Davey P, Tsao MN, et al.: Pseudoprogression following chemotadiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010, 37: 36-42.CrossRefPubMed Sanghera P, Perry J, Davey P, Tsao MN, et al.: Pseudoprogression following chemotadiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010, 37: 36-42.CrossRefPubMed
24.
go back to reference Gerstner ER, McNamara MB, Norden AD, LaFrankie D, Wen PY: Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neuroncol 2009, 94: 97-101. 10.1007/s11060-009-9809-4CrossRef Gerstner ER, McNamara MB, Norden AD, LaFrankie D, Wen PY: Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neuroncol 2009, 94: 97-101. 10.1007/s11060-009-9809-4CrossRef
25.
go back to reference Provenzale JM, Mukundan S, Barboriak DP: Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006,239(3):632-49. 10.1148/radiol.2393042031CrossRefPubMed Provenzale JM, Mukundan S, Barboriak DP: Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology 2006,239(3):632-49. 10.1148/radiol.2393042031CrossRefPubMed
26.
go back to reference Cao Y, Tsien CI, Nagesh V, Junck L, Ten HR, Ross BD, et al.: Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006,64(3):876-85. 10.1016/j.ijrobp.2005.09.001CrossRefPubMed Cao Y, Tsien CI, Nagesh V, Junck L, Ten HR, Ross BD, et al.: Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006,64(3):876-85. 10.1016/j.ijrobp.2005.09.001CrossRefPubMed
27.
go back to reference Chang S, Clarke J, Wen PY: Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma. J Clin Onc 2009, 107-11. Chang S, Clarke J, Wen PY: Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma. J Clin Onc 2009, 107-11.
28.
go back to reference Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, et al.: Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 2007,69(2):381-9. 10.1016/j.ijrobp.2007.03.019PubMedCentralCrossRefPubMed Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, et al.: Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 2007,69(2):381-9. 10.1016/j.ijrobp.2007.03.019PubMedCentralCrossRefPubMed
29.
go back to reference Hamstra A, Chenevert T, Moffat B, et al.: Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Nat Acad Scien 2005,102(46):16759-64. 10.1073/pnas.0508347102CrossRef Hamstra A, Chenevert T, Moffat B, et al.: Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Nat Acad Scien 2005,102(46):16759-64. 10.1073/pnas.0508347102CrossRef
30.
go back to reference Hamstra DA, Galbán CJ, Chenevert TL, et al.: Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008, 26: 3387-94. 10.1200/JCO.2007.15.2363PubMedCentralCrossRefPubMed Hamstra DA, Galbán CJ, Chenevert TL, et al.: Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008, 26: 3387-94. 10.1200/JCO.2007.15.2363PubMedCentralCrossRefPubMed
31.
go back to reference Chenevert TL, Stegman LD, Taylor JM, et al.: Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000, 92: 2029-36. 10.1093/jnci/92.24.2029CrossRefPubMed Chenevert TL, Stegman LD, Taylor JM, et al.: Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000, 92: 2029-36. 10.1093/jnci/92.24.2029CrossRefPubMed
32.
go back to reference Provenzale JM, York G, Serajuddin H, et al.: Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. Am J Roentgenol 2006, 187: 1036-42. 10.2214/AJR.04.0676CrossRef Provenzale JM, York G, Serajuddin H, et al.: Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms. Am J Roentgenol 2006, 187: 1036-42. 10.2214/AJR.04.0676CrossRef
33.
go back to reference Bian W, Khayal IS, Nelson SJ, et al.: Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion and diffusion imaging. Transl Oncol 2009, 2: 271-80.PubMedCentralCrossRefPubMed Bian W, Khayal IS, Nelson SJ, et al.: Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion and diffusion imaging. Transl Oncol 2009, 2: 271-80.PubMedCentralCrossRefPubMed
34.
go back to reference Tsien C, Galbán C, Chenevert T, et al.: Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma. J Clin Oncol 2010, 28: 2293-2299. 10.1200/JCO.2009.25.3971PubMedCentralCrossRefPubMed Tsien C, Galbán C, Chenevert T, et al.: Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma. J Clin Oncol 2010, 28: 2293-2299. 10.1200/JCO.2009.25.3971PubMedCentralCrossRefPubMed
35.
go back to reference Larson SM, Schwartz LH: 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med 2006,47(6):901-3.PubMed Larson SM, Schwartz LH: 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med 2006,47(6):901-3.PubMed
36.
go back to reference Backes H, Ullrich R, Jacobs AH, et al.: Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 2009, 26: 1960-67.CrossRef Backes H, Ullrich R, Jacobs AH, et al.: Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 2009, 26: 1960-67.CrossRef
37.
go back to reference Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352: 987-996. 10.1056/NEJMoa043330CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352: 987-996. 10.1056/NEJMoa043330CrossRefPubMed
Metadata
Title
Evaluation of early imaging response criteria in glioblastoma multiforme
Authors
Adam Gladwish
Eng-Siew Koh
Jeremy Hoisak
Gina Lockwood
Barbara-Ann Millar
Warren Mason
Eugene Yu
Normand J Laperriere
Cynthia Ménard
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-121

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue